Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
Jackson Center, PA – November 3, 2025 – Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development of an effective post-head-trauma treatment for Traumatic Brain Injury (TBI). The United States military, for example, has historically experienced rates of suicide among both active duty and veteran groups reaching as ...
Halberd Corporation Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform
Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies Jackson Center, PA – October 27, 2025 – Halberd Corporation (OTC: HALB) today announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's core technological approach and confirmed the feasibility of multi-modal behavioral analysis employing advanced artificial intelligence. Successful Technical ...
Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain Injury Recovery Monitoring, Among Other Medical Applications Jackson Center, PA – September 29, 2025 – Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp., a groundbreaking artificial intelligence platform that will revolutionize behavioral analysis for traumatic brain injury (TBI) research and clinical assessment. The proprietary platform represents the first commercial development of multi-modal behavioral signal fusion. Breaking ...
Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates
Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. Jackson Center, PA, May 28, 2025 – Halberd Corporation (OTC "HALB”) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease. We previously found that our patent-pending LDX medication is an incredibly ...
Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award! Jackson Center, PA, March 17, 2025 – Halberd Corporation (OTC "HALB”) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal government. Of the two technologies associated with Traumatic Brain Injuries (TBI)/Suicide Ideation for which we chose to pursue government funding, Athena’s success via the WatchDawg® Pilot ...
Halberd Update on WatchDawg® PTSD Treatment
Next Phase Pilot Study Jackson Center, PA December 2, 2024 – Halberd Corporation (OTC-PINK: "HALB”) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software performance and reporting improvements have been incorporated into ...